Umbrex is pleased to welcome Loddie Foose. Loddie, PhD helps clients unlock the limitless potential of their organizations and people. She supports senior healthcare executives in developing and strengthening strategies that will also enable high-performance execution in their teams, integrating core strategy development with transformational leadership approaches. Loddie has worked in the healthcare industry for two decades, both in operational / P&L roles and as a former management consultant with The Boston Consulting Group (BCG). Her experience spans biotech, pharma,…

Andrew McKee shares insights about the differences between US and Japan innovation and output in the Biopharma industry. As we’ve expanded our US-Japan services, we are often asked about the differences between the US and Japanese biopharma industry. There are several, and we recently hosted a members-only webinar in Japan about the differences between US and JP innovation and output.  Japan is, of course, a growing leader in biopharma and home to several top multinationals. Japan consistently ranks highly among…

Kian Beyzavi shares a post that takes a look at the driving factors behind innovation in Life Sciences.  The healthcare industry is changing worldwide.  The key trends contributing to this change stem from evolving behaviors and needs of the key stakeholders: Patient, Providers, Payors/Employers as well as emerging technologies: Patients are empowered, educated and tech savvy.  They increasingly demand the same user experience in managing their disease as they receive in other parts of their lives such as banking or…

Umbrex is pleased to welcome Rodolphe Lebrun with LDP Partner.  Rodolphe Lebrun is an advisor and interim executive for biotech, medtech and biopharma. He spent 5 years at McKinsey focusing on Life Sciences and led commercial excellence at AbbVie Belgium for 2 years. Prior to McKinsey, he was a R&D project manager in aerospace within the Safran group. Rodolphe supports Life Sciences companies across their lifecycle: raising venture capital as interim CEO for startups, reviewing go-to-market strategies in scale-ups and…